Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program

Aurore Perrot; Cyrille Hulin; Ariane Boumendil; Hamza Manjra; Antoine Leveque; Carolyne Croizier; Arthur Dony; Mohamad Mohty; Murielle Roussel; Salomon Manier; Frédérique Orsini-Piocelle; Loic Bauschert; Arthur Bobin; Laurent Frenzel; Laure Vincent; Claire Breal; Jean Richard Eveillard; Thomas Gerome; Mourad Tiab; Emilie Chalayer; Rakiba Belkhir; Clara Mariette; Perrine Moyer; Thomas Chalopin; Brieuc Cherel; Lydia Montes; Arthur Coste; Reza Tabrizi; Lionel Karlin; Daniella Robu; Amandine Huguet; Stéphanie Harel; Philippe Moreau

doi:10.3324/haematol.2024.286118

Open access journal of the Ferrata-Storti Foundation, a non-profit organization

Letters to the Editor

Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program

Aurore Perrot
Cyrille Hulin
Ariane Boumendil
Hamza Manjra
Antoine Leveque
Carolyne Croizier
Arthur Dony
Mohamad Mohty
Murielle Roussel
Salomon Manier
Frédérique Orsini-Piocelle
Loic Bauschert
Arthur Bobin
Laurent Frenzel
Laure Vincent
Claire Breal
Jean Richard Eveillard
Thomas Gerome
Mourad Tiab
Emilie Chalayer
Rakiba Belkhir
Clara Mariette
Perrine Moyer
Thomas Chalopin
Brieuc Cherel
Lydia Montes
Arthur Coste
Reza Tabrizi
Lionel Karlin
Daniella Robu
Amandine Huguet
Stéphanie Harel
Philippe Moreau

Hématologie, CHU de Toulouse, IUCT Oncopole, Toulouse

Hématologie, CHU Hôpital Haut Leveque, Bordeaux

Intergroupe Francophone du Myélome, Paris

Hématologie, Institut Paoli Calmettes, Marseille

Hématologie, Institut Cancerologie Strasbourg Europe, Strasbourg

Hématologie, CHU de Clermont Ferrand

Hématologie, CH Métropole Savoie, Chambéry

Hématologie, APHP St Antoine, Paris France

Hématologie, CHU de Limoges, Limoges

Hématologie, CHU de Lille, Lille France

Hématologie, CH d’Annecy, Annecy

Hématologie, Hôpital Saint Vincent, Lille

Hématologie CHU La Milétrie, Poitiers

Hématologie, APHP Necker, Paris

Hématologie, CHU de Montpellier, Montpellier

Hématologie, CH de Lorient, Lorient

Hématologie, CHU de Brest, Brest

Hématologie, CHU de Caen, Caen

Hématologie, CH de Vendée, La Roche sur Yon

Hématologie, CHU de Saint Etienne

Hématologie, APHP Bicetre, Paris

Hématologie, CHU de Grenoble, Grenoble

Hématologie, CHU de Nantes, Nantes

Hématologie, CHRU de Tours, Tours

Hématologie, Hôpital de Vannes, Vannes

Hématologie, CHU d’Amiens, Amiens

Hématologie, CHU de Reims, Reims

Hématologie, Hopital de Mont de Marsan, Mont-de-Marsan

Hématologie, CHU de Lyon Sud, Lyon

Hématologie, Hopital de Lens, Lens

Intergroupe Francophone du Myélome, Paris

Hématologie, APHP St Louis, Paris

Hématologie, CHU de Nantes, Nantes

Haematologica Early view Nov 21, 2024 https://doi.org/10.3324/haematol.2024.286118

Abstract

Not available.

Figures & Tables

Article Information

Early view : Letters to the Editor

DOI

https://doi.org/10.3324/haematol.2024.286118

Published

2024-11-21

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views

177

PDF Downloads

Statistics from Altmetric.com

No Data

Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program

Abstract

Figures & Tables

Article Information

Article Usage

Statistics from Altmetric.com

Download Citation

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More